Genetic Markers and Predictors of Antidepressant-induced Suicidality in Youth Depression
Overview
- Phase
- Not Applicable
- Intervention
- bupropion or lamotrigine
- Conditions
- Depression
- Sponsor
- Asan Medical Center
- Enrollment
- 80
- Locations
- 1
- Primary Endpoint
- Evaluation of Suicidal ideation and behavior
- Last Updated
- 6 years ago
Overview
Brief Summary
The objective of this study is to identification of genetic markers and predictors of antidepressant-induced suicidality in youth depression. Participants who take the standardized pharmacotherapy (bupropion or lamotrigine) for depression will be observed for 8 weeks. They will do several scales and genetic tests at visit 1 (week 0), visit 3 (week 4) and visit 4 (week 8)
Investigators
Hyo-Won Kim
Assistant professor, department of psychiatry, Asan Medical Center
Asan Medical Center
Eligibility Criteria
Inclusion Criteria
- •Aged between 11 and 18 years
- •Met the Kiddie-Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version (K-SADS-PL) diagnostic criteria for depressive episode or dysthymia
- •Intelligence quotient higher than 70 on the Korean Educational Developmental Institute's Wechsler Intelligence Scale for Children
Exclusion Criteria
- •presence of intellectual disability
- •presence of hereditary disorder
- •past and/or current history of acquired brain injury, like cerebral palsy
- •presence of seizure, other neurological disorder or sensory impairments
- •past and/or current history of pervasive developmental disorder
- •past and/or current history of schizophrenia, bipolar disorder or psychosis
- •presence of severe learning disorder
Arms & Interventions
Increased suicidality
Increase in suicidal ideation after taking the standardized pharmacotherapy (bupropion or lamotrigine) during 8 weeks.
Intervention: bupropion or lamotrigine
Non-increased suicidality
Non-increase of suicidal ideation after taking the standardized pharmacotherapy (bupropion or lamotrigine) during 8 weeks.
Intervention: bupropion or lamotrigine
Outcomes
Primary Outcomes
Evaluation of Suicidal ideation and behavior
Time Frame: 8 weeks
Using Columbia-Suicide Severity Rating Scale(C-SSRS)
Secondary Outcomes
- Evaluation of treatment effect of antidepressants(CDRS)(8 weeks)
- Evaluation of treatment effect of antidepressants (YMRS)(8 weeks)
- Evaluation of treatment effect of antidepressants(P-GBI)(8 weeks)
- Evaluation of treatment effect of antidepressants(CGI-S)(8 weeks)
- Genome wide association analysis(8 weeks)